Processing your request


please wait...
Stanford Law School Securities Class Action Clearinghouse a Collaboration with Cornerstone Research

Case Page

 

Endocyte, Inc.

Case Summary

Endocyte, Inc. Securities Litigation

Case Summary

Case Status:    DISMISSED    
On or around 12/17/2019 (Notice of voluntarily dismissal)

Filing Date: November 08, 2018

Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer.

On October 18, 2018, Endocyte issued a press release to announce the Proposed Merger between Endocyte and Novartis AG.

The Complaint alleges that on October 31, 2018, the Board authorized the filing of a materially incomplete and misleading preliminary Proxy Statement with the Securities and Exchange Commission, in violation of Sections 14(a) and 20(a) of the Exchange Act.

This case was voluntarily dismissed as moot on December 17, 2018.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.